Cipla said in the press note that it has received a warning letter from the United States Food and Drug Administration (USFDA).
The stock is trading down by more than 3% in the opening trade today.
“This is to inform you that further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019 by the United States Food and Drug Administration (USFDA), the Company has received a Warning Letter from USFDA,” the pharma company said.
The company remains committed to maintaining the highest standards of compliance and will work closely with the agency to comprehensively address all the observations, it added.
Stock view:
Cipla Ltd is currently trading at Rs414.30 down by Rs11.05 or 2.6% from its previous closing of Rs425.35 on the BSE.
For Quick Trial – 8871888787
or mail us here - support@researchicon.com
or visit - http://www.researchicon.com
إرسال تعليق